SMTL ID : 9sgh.1

Bimekizumab Fab in complex with human interleukin-17A

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.66 Å

Oligo State

hetero-2-2-2-mer

Ligands

6 x ZN: ZINC ION(Non-covalent)

ZN.1: 2 residues within 4Å: Chain B: D.151, H.189 2 PLIP interactions: 2 interactions with chain B Metal complexes: B:D.151, B:H.189 ZN.2: 1 residues within 4Å: Chain C: E.54 3 PLIP interactions: 2 interactions with chain C, 1 Ligand-Water interactions Metal complexes: C:E.54, C:E.54, H2O.2 ZN.3: 2 residues within 4Å: Chain D: D.74, H.76 3 PLIP interactions: 2 interactions with chain D, 1 Ligand-Water interactions Metal complexes: D:D.74, D:H.76, H2O.2 ZN.4: 1 residues within 4Å: Chain D: H.63 3 PLIP interactions: 1 interactions with chain D, 2 Ligand-Water interactions Metal complexes: D:H.63, H2O.2, H2O.2 ZN.6: 1 residues within 4Å: Chain E: H.63 2 PLIP interactions: 1 interactions with chain E, 1 Ligand-Water interactions Metal complexes: E:H.63, H2O.3 ZN.7: 2 residues within 4Å: Chain E: D.74, H.76 2 PLIP interactions: 2 interactions with chain E Metal complexes: E:D.74, E:H.76

1 x PO4: PHOSPHATE ION(Non-functional Binders)

PO4.5: 4 residues within 4Å: Chain B: S.28, R.30, G.68 Chain D: H.76 3 PLIP interactions: 2 interactions with chain B, 1 interactions with chain D Hydrogen bonds: B:S.28, B:R.30 Salt bridges: D:H.76

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Ungan, D. et al., IL-17A complexes with therapeutic antibodies exhibit distinct size distributions, potentially contributing to clinically observed immunogenicity. Mabs (2025)

Release Date

2025-10-29

Peptides

Bimekizumab Fab heavy-chain: AC
Bimekizumab Fab light-chain: BF
Interleukin-17A: DE

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

C
H

B
B

F
L

D
I

E
J

Bimekizumab Fab heavy-chain

Bimekizumab Fab light-chain

Interleukin-17A

Related Entries With Identical Sequence